Site icon Peter A. Hovis

Eureka Discoveries!

Eureka Newsletter

Correction: If you had trouble joining the BACKHOME study before, please try again using the link in this email.
STUDY SPOTLIGHT 🔬
Did you know that 1 in 5 Americans suffer from chronic low back pain, and it is the number one reason for opioid prescription use?

If you suffer from chronic low back pain, join the BACKHOME study! Your participation will help us develop better treatments.

What 
Join this online-only BACKHOME study and contribute to our knowledge about low back pain. This will help our research team at the University of California, San Francisco (UCSF) develop better treatments for you and others like you.

Who
You may be eligible if you are 18 years or older, have had low back pain for three months or more, and live in the United States.

When
If you join, we will send you a few surveys every 3 to 6 months over the next 2 years. The first survey will take the most time to complete because we’d like to learn about you and your experience with back pain. The next set of surveys will be much shorter in length. You can fill out the surveys on your computer or use your mobile phone whenever you have free time.

Learn more

Join the Study
Questions?
You can reach us by email at: BackHomeHelp@ucsf.edu.
STUDY SPOTLIGHT 🔬
Here is what our Citizen Scientists have to say!

A lot has changed since the COVID-19 pandemic began in 2020. So in February 2023, we asked our COVID-19 Citizen Scientists their thoughts on the state of COVID-19 in 2023. 9,862 Citizen Scientists responded, and we are excited to share the results.

Click here to read the first in a multi-part blog post where we share the results from the survey. We will continue to share more results in upcoming Newsletters. Stay tuned!

STUDY SPOTLIGHT 🔬
Thanks to our COVID-19 Citizen Scientists, we’re learning more and more about “Long COVID” every day!

We recently asked COVID-19 Citizen Science participants who had previously tested positive for COVID about their health after their initial illness. The scientific team at UCSF found that of those COVID-positive participants who responded to the survey, 32% reported Long COVID symptoms.

Factors that predicted Long COVID symptoms included the number of symptoms reported at initial infection, pre-infection symptoms of depression, and COVID variants prior to Omicron. Furthermore, we found that treatment with Paxlovid (nirmatrelvir/ritonavir) following a COVID-positive test among vaccinated, non-hospitalized individuals was not associated with prevalence of Long COVID symptoms or severity of Long COVID disease.

To read more about these findings, click here and here.

You can become a COVID-19 Citizen Scientist by visiting 
https://covid19.eurekaplatform.org/
Copyright © 2023 UCSF Eureka Platform, All rights reserved.
You are receiving this email because you have a registered account with the Eureka Platform.

Our mailing address is:

UCSF Eureka Platform
555 Mission Bay Blvd (South)
Suite 161

San Francisco, CA 94158

Add us to your address book

Want to change how you receive these emails?
You can update your preferences or unsubscribe from this list.

Exit mobile version
Skip to toolbar